The pharmacokinetics and pharmacodynamics of alogliptin in children, adolescents, and adults with type 2 diabetes mellitus

• Published in: European journal of clinical pharmacology Vol. 73; no. 3; pp. 279 - 288
• Main Authors: Dudkowski, Caroline, Tsai, Max, Liu, Jie, Zhao, Zhen, Schmidt, Eric, Xie, Jeannie
• Format: Journal Article
• Language: English
• Published: Berlin/Heidelberg Springer Berlin Heidelberg 01.03.2017; Springer Nature B.V
• Subjects: Adolescent; Adult; Area Under Curve; Biomedical and Life Sciences; Biomedicine; Child; Clinical Trial; Diabetes Mellitus, Type 2 - drug therapy; Diabetes Mellitus, Type 2 - metabolism; Dipeptidyl-Peptidase IV Inhibitors - adverse effects; Dipeptidyl-Peptidase IV Inhibitors - pharmacokinetics; Dipeptidyl-Peptidase IV Inhibitors - pharmacology; Dipeptidyl-Peptidase IV Inhibitors - therapeutic use; Female; Half-Life; Humans; Hypoglycemic Agents - adverse effects; Hypoglycemic Agents - pharmacokinetics; Hypoglycemic Agents - pharmacology; Hypoglycemic Agents - therapeutic use; Kinetics; Male; Pediatrics; Pharmacology; Pharmacology/Toxicology; Piperidines - adverse effects; Piperidines - pharmacokinetics; Piperidines - pharmacology; Piperidines - therapeutic use; Studies; Uracil - adverse effects; Uracil - analogs & derivatives; Uracil - pharmacokinetics; Uracil - pharmacology; Uracil - therapeutic use; Young Adult; Alogliptin; Pharmacodynamics; Pharmacokinetics; Pediatric patients; DPP-4 inhibition

Purpose The aim of this study is to determine the pharmacokinetics (PK) and pharmacodynamics (PD) of a single 12.5- or 25-mg dose of alogliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, in pediatric (children and adolescents) and adult subjects with type 2 diabetes mellitus (T2DM). Methods A rand...